Fortress Biotech

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Journey Medical Corp

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023 Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29 Company to hold conference call on May 22, 2023, at 4:30 p.m. ET SCOTTSDALE, Ariz.

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

Fortress Biotech (FBIO) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.18 per share a year ago.

Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates

Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline

Company to host conference call to discuss financial results and provide a corporate update on May 11, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 11, 2023 at 4:30 p.m. ET

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

Company is eligible to receive up to ~$140 million in potential late-stage development, regulatory and sales milestone payments plus royalties from 4DMT Company is eligible to receive up to ~$140 million in potential late-stage development, regulatory and sales milestone payments plus royalties from 4DMT

Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas' Short-Form Human Complement Factor H

Fortress expects to file a total of three new drug applications in 2023

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

Generated record total revenues of $73.7 million for the full year 2022

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ET

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

Subjects completed 16-week treatment with no significant safety issues

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

SCOTTSDALE, Ariz., March 07, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 35th Annual ROTH Conference, which is being held March 12-14, 2023.

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in two investor conferences in March 2023.

Fortress Biotech to Participate in Two March 2023 Investor Conferences

Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplant

Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients

Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex

MIAMI, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the closing of its previously announced registered direct offering and concurrent private placement. The Company issued 16.6 million shares of its common stock in the registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share was $0.835.

Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

MIAMI, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has entered into definitive agreements for the issuance and sale of 16.6 million shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share is $0.835.

Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Avenue Therapeutics

NEW YORK, NY / ACCESSWIRE / January 31, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI). About Avenue Therapeutics, Inc. Avenue Therapeutics, Inc. (Nasdaq:ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases.

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

SCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Ernest (Ernie) De Paolantonio has notified the Company that, effective January 27, 2023, he will step down as Chief Financial Officer of Journey Medical to pursue another opportunity. The Company also today announced the appointment of Joseph M. Benesch as Interim Chief Financial Officer, effective January 27, 2023.

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

Topline data expected in the first half of 2023 Topline data expected in the first half of 2023

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Phase 3, registrational studies remain on track for first half of 2023 topline data readout Phase 3, registrational studies remain on track for first half of 2023 topline data readout

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its Board of Directors. Dr. Lu is an accomplished executive with over 20 years of experience in a wide range of financial and drug development matters in the biotech and healthcare sectors as an investment banker, equity research analyst and executive at several biotech companies.

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

MIAMI, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia, today announced that the Company has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. (“Fuji”) for the development of dotinurad to include the Middle East and North Africa (“MENA”) and Turkey territories. The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States (“US”), United Kingdom, European Union and Canada.

Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

MIAMI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Fortress will participate in one-on-one meetings at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on Thursday, December 8, 2022 in Miami, FL.

News for Fortress Biotech Stock (FBIO)